期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

生物标志物预测非小细胞肺癌的疗效 被引量：1

Biomarker Is Predictor of Efficacy in Patients with Non-Small Cell Lung Cancer
下载PDF
导出
摘要 2010年3月11—13日．中国抗癌协会肺癌专业委员会和中国抗癌协会临床肿瘤学专业委员会联合主办了第七届“中国肺癌高峰论坛”，来自全国各地的300多位专家，讨论了生物标志物作为疗效预测因子在非小细胞肺癌（non—small cell lung cancer，NSCLC）临床上的应用问题，形成了作为非小细胞肺癌疗效预测因子的生物标志物之中国共识。
作者 吴一龙 廖美琳 周清华 王长利 陆舜 莫树锦 周彩存 王洁 马胜林 王绿化 张绪超 王俊 程颖 赫捷 许林 黄诚 毛伟敏 宋启斌 傅小龙 杨衿记 徐崇锐 杨学宁
机构地区 广东省人民医院肿瘤中心 上海市肺部肿瘤临床医学中心 天津医科大学总医院胸部肿瘤中心 天津医科大学附属肿瘤医院 香港中文大学威尔斯亲王医院 上海市肺科医院肿瘤科 北京大学临床肿瘤学院 浙江省肿瘤医院 中国医学科学院肿瘤医院 北京大学人民医院胸外科 吉林省肿瘤医院 江苏省肿瘤医院胸外科 福建省肿瘤医院肿瘤内科 湖北省肿瘤医院放疗科 复旦大学附属肿瘤医院
出处 《循证医学》 CSCD 2010年第4期237-241,共5页 The Journal of Evidence-Based Medicine
关键词 肺肿瘤 循证医学 共识 lung neoplasms evidence-based medicine consensus
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献29

  • 1Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or Carboplatin-Paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):947-957.
  • 2Maemondo M,Inoue A,Kobayashi K,et al.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J].N Engl J Med,2010,362(25):2380-2388.
  • 3Mitsudomi T,Morita S,Yatabe Y,et al.Gefitinib versus Cisplatin plus Docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405):An open label,randomised phase 3trial[J].Lancet Oncol,2010,11(2):121-128.
  • 4Rosell R,Moran T,Queralt C,et al.Screening for epidermal growth factor receptor mutations in lung cancer[J].N Engl J Med,2009,361(10):958-967.
  • 5Dahabreh IJ,Linardou H,Siannis F,et al.Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer[J].Clin Cancer Res,2010,16(1):291-303.
  • 6Goss GD,Lorimer I,Tsao MS,et al.A phase Ⅲ prospective randomized,double-blind,placebo-contrelled trial of the epidermal growth factor receptor inhibitor Gefitinb in completely resected stage Ⅰ B-Ⅲ A non-small cell lung cancer(NSCLC):NCIC CTG BR.19[J].J Clin Oncol(Meeting Abstracts),2010,28(18s):LBA7005.
  • 7Janjigian YY,Park BJ,Kris MG,et al.Impact on disease-free survival of adjuvant Erlotinib or Gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor(EGFR)mutations[J].J Clin Oncol(Meeting Abstracts),2009,27(15s):7523.
  • 8Kelly K,Chansky K,Gaspar LE,et al.Phase Ⅲ trial of maintenance Gefitinib or placebo after concurrent chemoradiotherapy and Docetaxel consolidation in inoperable stage Ⅲ non-small-cell lung cancer:SWOG S0023[J].J Clin Oncol,2008,26(15):2450-2456.
  • 9Eberhard DA,Giaccone G,Johnson BE.Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group:Standardization for use in the clinical trial setting[J].J Clin Oncol,2008,26(6):983-994.
  • 10Bai H,Mao L,Wang HS,et al.Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages Ⅲ B to Ⅳ non-small-cell lung cancer[J].J Clin Oncol,2009,27(16):2653-2659.

同被引文献15

  • 1Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemo- therapy[J].N EnglJ Med, 2006, 355(10): 983-991.
  • 2Chen S, ZhangJ, Wang R, et al. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCClex- pression better than high/positive ERCC1 expression? A meta-analysis m. Lung Cancer, 2010, 70(1): 63-70.
  • 3Turhal NS, Bas E, Er O, et al. ERCC1 is not expressed in hepato- cellular cancer: A turkish oncology group, gastrointestinal oncology subgroup study[J].J BUON, 2010, 15(4):794-796.
  • 4Ueda S, Shirabe K, Morita K, et al. Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatoceUular carcinomaS. Ann Surg Oncol, 2011, 18(4): 1204-1211.
  • 5Fautrel A, Andrieux L, Musso O, et al. Overexpression of the two nucleofide excision repair genes ERCC1 and XPC in humanhepato- cellular carcinoma[J]. J Hepatol, 2005, 43(2): 288-293.
  • 6Tsodikov OV, Ivanov D, Orelli B, et al. Structural basis for the re- cruitment of ERGC1-XPF to nucleofide excision repair complexes byXPA[J]. EMBOJ, 2007, 26(22): 4768-4776.
  • 7Croteau DL, Peng Y, Van Houten B. DNA repair gets physical: mapping an XPA-binding site on ERCCI[J]. DNA Repair(Amst), 2008, 7(5): 819-826.
  • 8Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer[J]. Chest, 2005, 127(3): 978-983.
  • 9Seyhan EC, Altm S, Cetinkaya E, et al. Prognostic significance of ERCC1 expression in resected non small cell lung carcinoma[J].Ann Thorac Cardiovasc Surg, 2011, 17(2): 110-117.
  • 10Usanova S, Pite-Staffa A, Sied U, et al. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand~..rosslink repair andlow ERCC1-XPF expression[J]. Mol Cancer, 2010, 9:248-259.

引证文献1

二级引证文献1

循证医学
2010年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部